Recombinant CA8 antibody (full length)
Quick Overview for Recombinant CA8 antibody (full length) (ABIN7877777)
Target
See all CA8 AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- full length
-
Purpose
- CA8 Antibody / Carbonic Anhydrase VIII
-
Purification
- Protein A/G affinity
-
Immunogen
- Recombinant full-length human protein was used as the immunogen for the CA8 antibody.
-
Isotype
- IgG1, kappa
-
-
-
-
Application Notes
- Optimal dilution of the CA8 antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Aliquot the CA8 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- CA8 (Carbonic Anhydrase VIII (CA8))
-
Alternative Name
- CA8
-
Background
- The protein encoded by this gene was initially named CA-related protein because of sequence similarity to other known carbonic anhydrase genes. However, the gene product lacks carbonic anhydrase activity (i.e., the reversible hydration of carbon dioxide). The gene product continues to carry a carbonic anhydrase designation based on clear sequence identity to other members of the carbonic anhydrase gene family. The absence of CA8 gene transcription in the cerebellum of the lurcher mutant in mice with a neurologic defect suggests an important role for this acatalytic form. Mutations in CA8 gene causes neuropathology, such as ataxia, mild mental retardation and the predisposition to quadrupedal gait. It is also associated with the development of colorectal and lung cancers. Additionally, it is upregulated in various cancers.
-
UniProt
- P35219
Target
-